File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: A Large Cohort Study Examining the Effects of Long-Term Entecavir on Hepatocellular Carcinoma and HBsAg Seroclearance

TitleA Large Cohort Study Examining the Effects of Long-Term Entecavir on Hepatocellular Carcinoma and HBsAg Seroclearance
Authors
Issue Date2018
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The Liver Meeting 2018, American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, 9-13 November 2018. Abstracts in Hepatology, 2018, v. 68 n. Suppl. 1, p. 260A How to Cite?
AbstractBackground: Real world studies examining reduction of risk of hepatocellular carcinoma (HCC) in patients receiving antivirals are limited either by the small-sized cohort studies, or data insufficiency and heterogeneity in electronic database with short follow-up duration. We aim to examine the long-term outcome of patients receiving entecavir treatment on HCC incidence and HBsAg seroclearance. Methods: Incidence of HCC in 1225 entecavir-treated patients between 2002 and 2015 was compared with the HCC incidence estimated using the REACH-B, GAG-HCC and CU-HCC scores. Standardized incidence ratios (SIR) were calculated. Impact of entecavir treatment on HBsAg seroclearance was explored. Results: The median follow-up of the cohort was 6.6 years, with 66 incidence cases of HCC. Using the REACH-B model, the reduction of HCC risk was significant from year 6 onwards with SIR of 0.68 (95% CI 0.535-0.866) at year 10. In subgroup patients without cirrhosis, consistent risk reduction was observed since the fifth year and SIR reached 0.51 (95% CI 0.271-0.704) by year 10. Benefit in cirrhotic patients were demonstrated when using the GAG-HCC and CU-HCC score, with SIR at year 10 being 0.38 (95% CI 0.259-0.544) and 0.46 (95% CI 0.314-0.659) respectively. The cumulative rate of HBsAg seroclearance was 5.2%. HBsAg level at third year of treatment and baseline-to-3-year percentage reduction were predictive of subsequent HBsAg seroclearance. Conclusion: Long-term entecavir therapy was associated with significant reduction in the risk of HCC in the real world. However, HBsAg seroclearance rate remained low. Additional therapy should be considered in patients with adverse predictive factor for subsequent HBsAg seroclearance.
DescriptionPoster Presentation - no. 437
Persistent Identifierhttp://hdl.handle.net/10722/269510
ISSN
2017 Impact Factor: 14.079
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorKo, KL-
dc.contributor.authorTo, WP-
dc.contributor.authorMak, LY-
dc.contributor.authorSeto, WKW-
dc.contributor.authorFung, JYY-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2019-04-24T08:09:09Z-
dc.date.available2019-04-24T08:09:09Z-
dc.date.issued2018-
dc.identifier.citationThe Liver Meeting 2018, American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, 9-13 November 2018. Abstracts in Hepatology, 2018, v. 68 n. Suppl. 1, p. 260A-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/269510-
dc.descriptionPoster Presentation - no. 437-
dc.description.abstractBackground: Real world studies examining reduction of risk of hepatocellular carcinoma (HCC) in patients receiving antivirals are limited either by the small-sized cohort studies, or data insufficiency and heterogeneity in electronic database with short follow-up duration. We aim to examine the long-term outcome of patients receiving entecavir treatment on HCC incidence and HBsAg seroclearance. Methods: Incidence of HCC in 1225 entecavir-treated patients between 2002 and 2015 was compared with the HCC incidence estimated using the REACH-B, GAG-HCC and CU-HCC scores. Standardized incidence ratios (SIR) were calculated. Impact of entecavir treatment on HBsAg seroclearance was explored. Results: The median follow-up of the cohort was 6.6 years, with 66 incidence cases of HCC. Using the REACH-B model, the reduction of HCC risk was significant from year 6 onwards with SIR of 0.68 (95% CI 0.535-0.866) at year 10. In subgroup patients without cirrhosis, consistent risk reduction was observed since the fifth year and SIR reached 0.51 (95% CI 0.271-0.704) by year 10. Benefit in cirrhotic patients were demonstrated when using the GAG-HCC and CU-HCC score, with SIR at year 10 being 0.38 (95% CI 0.259-0.544) and 0.46 (95% CI 0.314-0.659) respectively. The cumulative rate of HBsAg seroclearance was 5.2%. HBsAg level at third year of treatment and baseline-to-3-year percentage reduction were predictive of subsequent HBsAg seroclearance. Conclusion: Long-term entecavir therapy was associated with significant reduction in the risk of HCC in the real world. However, HBsAg seroclearance rate remained low. Additional therapy should be considered in patients with adverse predictive factor for subsequent HBsAg seroclearance.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.relation.ispartofAmerican Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2018-
dc.titleA Large Cohort Study Examining the Effects of Long-Term Entecavir on Hepatocellular Carcinoma and HBsAg Seroclearance-
dc.typeConference_Paper-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.hkuros297387-
dc.identifier.volume68-
dc.identifier.issueSuppl. 1-
dc.identifier.spage260A-
dc.identifier.epage260A-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats